Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clevudine + adefovir dipivoxil is an investigational combination of two antiviral agents used for the treatment of chronic hepatitis B virus (HBV) infection. Clevudine is a nucleoside analog that inhibits HBV DNA polymerase, thereby suppressing viral replication. Adefovir dipivoxil is a diester prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. After conversion to its active metabolite, adefovir diphosphate, it inhibits HBV DNA polymerase (reverse transcriptase) by competing with deoxyadenosine triphosphate and causing chain termination after incorporation into viral DNA[2][3][5]. The combination aims to enhance antiviral efficacy and reduce the risk of resistance in patients with chronic hepatitis B.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clevudine + adefovir dipivoxil.